The Clinical Neuro-Oncology Laboratory (Meola/Chang)
Welcome to Antonio Meola, MD, PhD and Steven D. Chang, MD's Clinical Neuro-Oncology Laboratory. Our Lab investigates the outcomes of patients affected with brain, skull base and spine tumors. The goal of the laboratory is to improve patients’ care and outcome by analyzing clinical data from thousands of patients treated at our institution, with surgery as well as with other innovative treatments, such as stereotactic radiosurgery (SRS), by Cyberknife. Retrospective analysis of large patient cohorts and of big-data databases allows re-defining the indications for treatment, refining the surgical technique and identifying new fields of application of minimally-invasive techniques. Our philosophy is “from patients to numbers and from numbers to patients”: data collected from our clinical experience are used for the benefit of the next generation of patients. Our laboratory collaborates with several clinical programs including the Brain Tumor Program, the Cyberknife Program, and the Neurogenetics Program. Thus, we focus on the broadest possible spectrum of tumors of the nervous system, ranging from the most common conditions to the most rare, such as the neurogenetic syndromes.
Moreover, the Laboratory is strongly connected with other national and international institutions, in order to develop collaborations on prospective trials and large-scale datasets in any field of neuro-oncology.
The goal of our Laboratory is to improve patients’ care and outcomes by analyzing clinical data from thousands of patients treated at our institution. Our current primary areas of interest are benign tumors, brain and spine metastases, and neurogenetic disorders.
Our lab is led by Dr. Antonio Meola and Dr. Steven D. Chang, and proudly hosts talented young clinical scientists from around the world.